4.8 Review

Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?

期刊

JOURNAL OF HEPATOLOGY
卷 78, 期 1, 页码 207-216

出版社

ELSEVIER
DOI: 10.1016/j.jhep.2022.08.036

关键词

HCC; liver cancer; surveillance; biospecimen

向作者/读者索取更多资源

Hepatocellular carcinoma (HCC) is a major contributor to cancer-related deaths globally due to inadequate early detection strategies. Current screening recommendations have several deficiencies, including suboptimal sensitivity and poor adherence. Blood-based biomarkers show promise but require validation and logistical solutions before clinical implementation. Maturing validation cohorts, such as the Hepatocellular Carcinoma Early Detection Study and the Texas Hepatocellular Carcinoma Consortium, are expected to provide robust validation for candidate biomarkers.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, in part because of inadequate early detection strategies. Current recommendations for screening consist of semi-annual abdominal ultrasound with or without serum alpha-fetoprotein in patients with cirrhosis and in demographic subgroups with chronic hepatitis B infection. However, this screening strategy has several deficiencies, including suboptimal early-stage sensitivity, false positives with subsequent harms, inter-operator variability in ultrasound performance, and poor adherence. A blood-based biomarker with sufficient performance characteristics for early-stage disease could overcome several of these barriers to improving early-stage detection. However, prior to use of a biomarker for screening in clinical practice, a multistep validation is required in order to understand test performance characteristics. These steps include case-control validation, followed by validation in prospective cohorts of at-risk patients. Until recently, we lacked adequate longitudinal validation cohorts for early HCC detection; however, several validation cohorts are maturing, including the Hepatocellular Carcinoma Early Detection Study and the Texas Hepatocellular Carcinoma Consortium, which will allow for rigorous validation of candidate biomarkers. While there are several promising biomarkers awaiting validation, in order to supplant abdominal ultrasound, a candidate biomarker must show adequate test performance and overcome practical hurdles to ensure adoption in clinical practice. The promise of blood-based biomarkers is significant, especially given the limitations of ultrasound-based screening; however, they require adequate validation and several logistical obstacles must be overcome prior to clinical implementation. (c) 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据